 LA JOLLA, Calif., Feb. 10, 2021 PRNewswire -- Regulus Therapeutics Inc. Nasdaq: RGLS, a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs the Company or Regulus, today announced it has completed enrollment of the first... 